Abstract
- Population : Immunocompetent children aged 3–24 months
- Intervention: One or two doses of MenA conjugate vaccine (5 µg dosage)
- Comparison: No MenA vaccination
- Outcome : Serious adverse events following immunization
What is the incidence of serious adverse events following any dose of MenA conjugate vaccine in immunocompetent children aged 3–24 months?
GRADE table
Newborn
GRADE
meningitis A
Meningococcal disease
